The Role of ACE I/D Gene Mutations in The Etiology of Buergers’s Disease

Filiz Ozen 1, Nadir Kocak 2, Atilla Orhan 3, Taha Tahir Bekci 4 *
More Detail
1 Goztepe Education and Research Hospital, Department of Genetic, Istanbul
2 Konya Education and Research Hospital, Department of Genetic, Konya
3 Konya Education and Research Hospital, Department of Cardiovascular Surgery, Konya
4 Konya Education and Research Hospital, Department of Pulmonary Medicine, Konya
* Corresponding Author
EUR J BASIC MED SCI, Volume 2, Issue 1, pp. 6-11.
Download Full Text (PDF)


Thromboangiitis obliterans (TAO), which is also known as Buerger’s disease, is a disease characterized by segmental inflammation together with vasoactive phenomena in the arteries and veins of the extremities. In the present study, the relationship between angiotensin-converting enzyme (ACE) insertion/deletion (I/D) gene mutations, which is known to be involved in vasodysfunction, and TAO was determined. Because of this relationship, it was aimed to determine whether the distribution of angiotensin-converting enzyme (ACE) insertion / deletion (I / D) gene mutations in patients with Thromboangiitis obliterans (TAO) is different from healthy subjects in the control group. Eighty patients who were previously diagnosed with TAO were included in the study. The patients were determined based on Olin’s criteria. The control group consisted of 88 healthy volunteers. DNA isolation was performed by venous blood from the patients in both groups. The DNAs were amplified via polymerase chain reaction (PCR) using appropriate primers, the amplicons were eluted by running in 1% agarose gel, and defined via staining. In addition to the significant difference between the patient and control groups in terms of age and smoking due to the selection criteria (Olin’s criteria), a statistically significant difference was also determined between the groups in terms of the distribution of the ACE I/D gene polymorphism. The significant difference between groups with respect to the ACE I/D polymorphism, together with the smokinglike effects of ACE on the cardiovascular system, reveal a consequence which should not be neglected.


Ozen F, Kocak N, Orhan A, Bekci TT. The Role of ACE I/D Gene Mutations in The Etiology of Buergers’s Disease. Eur J Basic Med Sci. 2012;2(1):6-11.


  • Buerger L. Thromboangiitis obliterans: a study of the vascular lesions leading to presenile gangrene. Am J Med Sci 1952; 136: 567-80.
  • Buerger L. The circulatory disturbance of the extremities: including gangrene, vasomotor and trophic disorders. Philadelphia, Saunders, 1924.
  • Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The changing clinical spectrum of thromboangiitis obliterans (Buerger’s disease). Circulation 1990; 82: 3-8.
  • Shionoya S. Diagnostic criteria of Buerger’s disease. Int J Cardiol 1998; 1:243-5.
  • Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med 2000; 343: 864-9.
  • Idem. The rise and fall and resurgence of thromboangiitis obliterans (Buerger’s disease). Acta Pathol Jpn 1989; 39: 153-8.
  • Idem. Thromboangiitis obliterans (Buerger’s disease) in women. Medicine (Baltimore) 1987; 66: 65-72.
  • Hoffman D, Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health 1997; 50: 307-64.
  • Hoffmann D, Wynder EL. Chemical constituents and bioactivity of tobacco smoke. In Tobacco: A Major International Hazard, No 74; Zaridze, DG, Peto, R, Eds; International Agency for Research on Cancer, IARC Scientific Publications: Lyon, France, 1986; 145-66.
  • Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT, Gupta PC, Hackshaw A, Matos E, Samet J, Sitas F, Smith J, Stayner L, Straif K, Thun MJ, Wichmann HE, Wu AH, Zaridze D, Peto R, Doll R. Tobacco smoke and cancer: recent epidemiological evidence. J Natl Cancer Inst 2004; 96: 99-105.
  • Pryor WA, Curch DF, Evans MD, Rice WY, Hayes JR. A comparison of the free radical chemistry of tobacco-burning cigarettes and cigarettes that only heat tobacco. Free Radic Biol Med 1990; 8: 275-79.
  • Environmental Protection Agency. Respiratory Health Effects of Passive Smoking: Lung Cancer and Other Disorders; EPA Publications: Washington DC, USA, 1992.
  • Heidrich J, Wellmann J, Heuschmann PU, Kraywinkel K, Keil U. Mortality and morbidity from coronary heart disease attributable to passive smoking. Eur Heart J 2007; 28: 2498-502.
  • Valavanidis A, Vlachogianni T, Fiotakis K. Tobacco Smoke: Involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. Int J Environ Res Public Health 2009; 445-62.
  • Glantz SA, Parmley WW. Passive smoking and heart disease: mechanisms and risk. JAMA 1996; 273:1047-53.
  • Terashima T, Klut ME, English D, et al. Cigarette smoking causes sequestration of polymorphonuclear leukocytes released from the bone marrow in lung microvessels. Am J Respir Cell Mol Biol 1999; 20:171-7.
  • Makita S, Nakamura M, Murakami H, Komoda K, Kawazoe K, Hiramori K. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger’s disease). Circulation 1996; 94: Suppl II: 211–15.
  • Erdos EG, Skidgel RA. The angiotensin I-converting enzyme. Lab Invest 1987; 56: 345–48.
  • Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993; 87:1816-28.
  • Samani NJ, Swales JD. Molecular biology of the vascular rennin angiotensin system. Blood Vessels 1991; 28: 210-6.
  • Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1995; 86: 1343-6.
  • Carey RM, Siragy HM. Newly recognized components of the rennin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003; 24: 261–71.
  • Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11: 194–205.
  • Ferrario CM, Strawn WB. Role of the renin-angiotensin system and pro-inflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121–28.
  • Paul M, Poyan Mehr A, Kreutz R. Physiology of local reninangiotensin systems. Physiol Rev 2006; 86: 747–803.
  • Orth T, Allen J, Wood JG, Gonzalez NC. Plasma from conscious hypoxic rats stimulates leukocyte-endothelial interactions in normoxic cremaster venules. J Appl Physiol 2005; 99: 290–7.
  • Suzuki H, Frank GD, Utsunomiya H, Higuchi S, Eguchi S. Current understanding of the mechanism and role of ROS in angiotensin II signal transduction. Curr Pharm Biotechnol 2006; 7: 81–6.
  • Wood JG, Johnson JS, Mattioli LF, Gonzalez NC. Systemic hypoxia promotes leukocyte-endothelial adherence via reactive oxidant generation. J Appl Physiol 1999; 87: 1734–40.
  • Soubrier F, Hubert C, Testut P, Nadaud S, Alhenc-Gelas F, Corvol P. Molecular biology of the angiotensin I converting enzyme, I: biochemistry and structure of the gene. J Hypertens 1993; 11: 471-6.
  • Baudin B. New aspect on angiotensin-converting enzyme: from gene to disease. Clin Chem Lab Med 2002; 40: 256-65.
  • Rieder MJ, Taylor SL, Clark AG, Nickerson DA. Sequence variation in the human angiotensin converting enzyme. Nat Genet 1999; 22: 59-62.
  • Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin-1-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
  • Prasad A, Narayanan S, Waclawiw MA, Epstein N, Quyyumi AA. The insertion/deletion polymorphism of the angiotensin-converting enzyme gene determines coronary vascular tone and nitric oxide activity. J Am Coll Cardiol 2000; 36: 1579-86.
  • Kitsios G, Zintzaras E. ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation. BMC Medical Genetics 2009; 10: 50-60.
  • Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.
  • Marian AJ, Yu Q, Workman R, Greve G, Roberts R. Angiotensin converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993; 342: 1085-6.
  • Butler R, Morris AD, Struthers AD. Angiotensin-converting enzyme gene polymorphism and cardiovascular disease. Clin Sci 1997; 93: 391-400.
  • Alvarez R, Reguero JR, Batalla A, Iglesias-Cubero G, Cortina A, Alvarez V, et al. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res 1998; 40: 375-9.
  • Alvarez R, Terrados N, Ortolano R, Iglesias-Cubero G, Reguero JR, Batalla A, et al. Genetic variation in the rennin-angiotensin system and athletic performance. Eur J Appl Physiol 2000; 82: 117-20.
  • Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease: metaanalyses of small and large studies in whites. Arterioscler Thromb Vasc Biol 2000; 20: 484-92.
  • Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H, van Gilst WH. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J 1996; 17: 787–94.
  • Chadwick IG, O’Toole L, Morice AH, Yeo WW, Jackson PR, Ramsay LE. Pressor and hormonal responses to angiotensin I infusion in healthy subjects of different angiotensinconverting enzyme genotypes. J Cardiovasc Pharmacol 1997; 29: 485–9.
  • Olin JW. Thromboangiitis obliterans (Buerger’s disease). In: Rutherford RB, editor. Vascular surgery. 6th ed. Vol. 1, Philadelphia: W. B. Saunders; 2005; 404-19.
  • Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
  • Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, Hennekens CH. A prospective evaluation of an angiotensinconverting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995;332:706–11.